Innovating Skin Therapeutics for Global Impact
Ahammune Biosciences is reimagining therapeutic solutions to address autoimmune skin diseases and restore skin health.
About Ahammune Biosciences
Ahammune Biosciences, based in Pune, India, is a biotech company focusing on therapeutic innovations for autoimmune skin diseases:
Core Innovation: Developing a new drug candidate for vitiligo (AB1001), which has completed Phase 1 trials with a first-in-class mechanism of action.
Market Potential: Global vitiligo market is estimated at $4.3B by 2027.
Intellectual Property: 3 patents filed, with 1 granted in India.
Clinical Efficacy: AB1001 gel is designed for topical application twice daily over five months, showing a safe profile for long-term use.
Research-Driven Leadership: Led by experts in dermatology and molecular biology, leveraging decades of research in skin biology.
Meet the Founders:
Fund I
BioTech
Naganand and Suri are not merely Ahammune's investors, they are our invaluable partners who work with us to translate our vision. Being entrepreneurs themselves, they really understand the challenges of a startup company and are always there to guide the founder with their tremendous experience.
Parul Ganju
Where We Fuel Innovation and Sustainable Growth
We partner with visionary founders across these industries, bridging bold ideas with resources for real-world impact and lasting change.
Stay Inspired with Our Latest Articles
Explore insights and stories that fuel startup innovation through our curated articles and expert perspectives.
Ready to Build the Future Together?
Let’s turn your bold ideas into transformative realities. with Ideaspring Capital to scale innovation, accelerate growth, and make a lasting impact in the world of technology.
